0000950170-25-101985 | 10-Q | XBRL Viewer | Syndax Pharmaceuticals INC

Label	Element	Value
Depreciation And Related Adjustment	sndx_DepreciationAndRelatedAdjustment	$ 0
Depreciation And Related Adjustment	sndx_DepreciationAndRelatedAdjustment	6,000
Accrued Royalty Interest Expense	sndx_AccruedRoyaltyInterestExpense	18,954,000
Accrued Royalty Interest Expense	sndx_AccruedRoyaltyInterestExpense	4,930,000
Prepaid Inventory	sndx_PrepaidInventory	2,742,000
Prepaid Inventory	sndx_PrepaidInventory	2,009,000
Collaboration Loss	sndx_CollaborationLoss	9,400,000
Cost of Product Sales	sndx_CostOfProductSales	1,279,000
Cost of Product Sales	sndx_CostOfProductSales	0
Cost of Product Sales	sndx_CostOfProductSales	2,164,000
Cost of Product Sales	sndx_CostOfProductSales	0
Cost of Product Sales	sndx_CostOfProductSales	1,279,000
Cost of Product Sales	sndx_CostOfProductSales	0
Cost of Product Sales	sndx_CostOfProductSales	2,164,000
Cost of Product Sales	sndx_CostOfProductSales	0
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	545,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	545,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	468,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	468,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	309,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	309,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	237,000
Employee withholdings ESPP	sndx_EmployeeWithholdingsEspp	237,000
Stock based compenstion	sndx_StockBasedCompenstion	13,787,000
Stock based compenstion	sndx_StockBasedCompenstion	9,896,000
Stock based compenstion	sndx_StockBasedCompenstion	24,167,000
Stock based compenstion	sndx_StockBasedCompenstion	18,795,000
Personnel Cost and Other Expenses	sndx_PersonnelCostAndOtherExpenses	18,997,000
Personnel Cost and Other Expenses	sndx_PersonnelCostAndOtherExpenses	14,861,000
Personnel Cost and Other Expenses	sndx_PersonnelCostAndOtherExpenses	35,528,000
Personnel Cost and Other Expenses	sndx_PersonnelCostAndOtherExpenses	29,202,000
Current Portion Of Capital Lease	sndx_CurrentPortionOfCapitalLease	6,000
Current Portion Of Capital Lease	sndx_CurrentPortionOfCapitalLease	9,000
Accrued Milestone Costs	sndx_AccruedMilestoneCosts	5,000,000
Accrued Milestone Costs	sndx_AccruedMilestoneCosts	10,600,000
Increase Decrease In Collaboration Receivable	sndx_IncreaseDecreaseInCollaborationReceivable	(31,547,000)
Increase Decrease In Collaboration Receivable	sndx_IncreaseDecreaseInCollaborationReceivable	(4,129,000)
Noncash Operating Lease Expense	sndx_NoncashOperatingLeaseExpense	393,000
Noncash Operating Lease Expense	sndx_NoncashOperatingLeaseExpense	486,000
Collaboration Expense Due To Counterparty	sndx_CollaborationExpenseDueToCounterparty	4,300,000
Collaboration receivable	sndx_CollaborationReceivable	16,600,000
Potential Milestone Payments Upon Achievement Of Milestone	sndx_PotentialMilestonePaymentsUponAchievementOfMilestone	220,000,000
Potential Milestone Payments Upon Achievement Of Milestone	sndx_PotentialMilestonePaymentsUponAchievementOfMilestone	99,000,000
Potential Milestone Payments Upon Achievement Of Milestone	sndx_PotentialMilestonePaymentsUponAchievementOfMilestone	68,000,000
Potential Milestone Payments Upon Achievement Of Milestone	sndx_PotentialMilestonePaymentsUponAchievementOfMilestone	119,500,000
Potential Milestone Payments Upon Achievement Of Milestone	sndx_PotentialMilestonePaymentsUponAchievementOfMilestone	78,500,000
Capital Lease Less Current Portion	sndx_CapitalLeaseLessCurrentPortion	1,325,000
Capital Lease Less Current Portion	sndx_CapitalLeaseLessCurrentPortion	$ 1,578,000
License Agreements Expiration Period	sndx_LicenseAgreementsExpirationPeriod	10 years
License Agreements Expiration Period	sndx_LicenseAgreementsExpirationPeriod	10 years
Development and regulaotry milestones Expenses	sndx_DevelopmentAndRegulaotryMilestonesExpenses	$ 31,000,000
Development and regulaotry milestones Expenses	sndx_DevelopmentAndRegulaotryMilestonesExpenses	$ 41,000,000
Number Of Pre Funded Warrants Exercised For Common Stock	sndx_NumberOfPreFundedWarrantsExercisedForCommonStock	285,714
Aggregate Potential Milestone Payable	sndx_AggregatePotentialMilestonePayable	$ 70,000,000
Aggregate Potential Milestone Payable	sndx_AggregatePotentialMilestonePayable	250,000,000
Product Revenue Allowance	sndx_ProductRevenueAllowance	5,204,000
Product Revenue Allowance	sndx_ProductRevenueAllowance	849,000
Accrued Clinical Costs Current	sndx_AccruedClinicalCostsCurrent	21,203,000
Accrued Clinical Costs Current	sndx_AccruedClinicalCostsCurrent	23,869,000
Prepaid Subscriptions	sndx_PrepaidSubscriptions	1,471,000
Prepaid Subscriptions	sndx_PrepaidSubscriptions	1,605,000
Prepaid State and Local Taxes	sndx_PrepaidStateAndLocalTaxes	359,000
Prepaid State and Local Taxes	sndx_PrepaidStateAndLocalTaxes	298,000
Upfront Payments	sndx_UpfrontPayments	117,000,000
Collaboration Receivable, Net	sndx_CollaborationReceivableNet	12,316,000
Collaboration Receivable, Net	sndx_CollaborationReceivableNet	0
Accrued Selling General and Administrative Costs	sndx_AccruedSellingGeneralAndAdministrativeCosts	5,582,000
Accrued Selling General and Administrative Costs	sndx_AccruedSellingGeneralAndAdministrativeCosts	4,258,000
Personnel cost and other General expenses	sndx_PersonnelCostAndOtherGeneralExpenses	19,307,000
Personnel cost and other General expenses	sndx_PersonnelCostAndOtherGeneralExpenses	4,153,000
Personnel cost and other General expenses	sndx_PersonnelCostAndOtherGeneralExpenses	38,389,000
Personnel cost and other General expenses	sndx_PersonnelCostAndOtherGeneralExpenses	8,258,000
Milestone Payment Due	sndx_MilestonePaymentDue	5,800,000
Collaboration Payable, Current	sndx_CollaborationPayableCurrent	0
Collaboration Payable, Current	sndx_CollaborationPayableCurrent	19,231,000
Royalty Payable	sndx_RoyaltyPayable	4,783,000
Royalty Payable	sndx_RoyaltyPayable	307,000
Milestone Paid	sndx_MilestonePaid	10,000,000
Royalty interest financing liability, less current portion	sndx_RoyaltyInterestFinancingLiabilityLessCurrentPortion	324,413,000
Royalty interest financing liability, less current portion	sndx_RoyaltyInterestFinancingLiabilityLessCurrentPortion	331,565,000
Milestone Expenses Paid	sndx_MilestoneExpensesPaid	5,000,000
Par Value Adjustments	sndx_ParValueAdjustments	1,000
Commercialization Milestones And Tiered Royalties	sndx_CommercializationMilestonesAndTieredRoyalties	$ 230,000,000

Royalty Interest Financing Liability - Schedule of Term Loan Payables (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Purchase and Sale Agreement [Line Items]
Current portion of royalty interest financing liability	$ 19,435	$ 12,116

Print Document
Details Royalty Interest Financing Liability - Schedule of Term Loan Payables (Details) Uncategorized Uncategorized Items - sndx-20250630_htm.xml All Reports